Company intelligence / Profile preview

EpiEndo Pharmaceuticals

Ownership: Private
Employees: ~20
Development stage: Other

Overview

EpiEndo’s lead asset, glasmacinal (EP395), has completed Phase 2a trials in COPD patients. The drug demonstrated good safety/tolerability over 12 weeks, reduced sputum neutrophil elastase and MPO levels, showed anti-inflammatory effects without antimicrobial resistance risk, and enhanced host defense response. Four clinical studies have been conducted to date with positive safety/pharmacology results.

Therapeutic areas: GastroenterologyPulmonology
Modalities: Small molecules (specifically, non-antibiotic macrolides called Barriolides™)
Industry: Biotech

Drug pipeline

1 asset

glasmacinal

Partnerships

AlveoliX AG – partnership to develop gut-on-chip models for ulcerative colitis research (“EpicoliX Project”).Academic collaborations implied but not detailed.

Beyond the preview

Go deeper on EpiEndo Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiEndo Pharmaceuticals.